TG003: Selective Clk1/2 Inhibitor for Alternative Splicin...

2025-12-20

TG003: Selective Clk1/2 Inhibitor for Alternative Splicing Modulation

Executive Summary: TG003 is a highly selective Cdc2-like kinase (Clk) inhibitor, primarily targeting Clk1 and Clk2 with nanomolar IC₅₀ values, making it a reliable reagent for dissecting the Clk-mediated phosphorylation pathway in alternative splicing research (APExBIO). TG003 demonstrates competitive ATP binding inhibition (K_i = 0.01 μM) and is effective in cell and animal models, including reversal of Clk-induced developmental defects and modulation of splicing in muscular dystrophy models. The specificity profile includes low nanomolar activity against Clk1 (20 nM), Clk2 (200 nM), and Clk4 (15 nM), with limited activity toward Clk3 (>10 μM), and casein kinase 1 inhibition as a secondary effect. In vivo, TG003 rescues splicing phenotypes and supports studies on platinum resistance in ovarian cancer by modulating Clk2-mediated BRCA1 phosphorylation (Jiang et al., 2024). The compound is insoluble in water but highly soluble in DMSO and ethanol, with established protocols for dosing and storage (APExBIO).

Biological Rationale

The Cdc2-like kinase (Clk) family regulates mRNA splice site selection through phosphorylation of serine/arginine-rich (SR) proteins involved in pre-mRNA processing (Jiang et al., 2024). Dysregulation of Clk activity affects alternative splicing events implicated in cancer, neuromuscular disorders, and developmental biology. Clk2 is upregulated in ovarian cancer tissues and is associated with resistance to platinum-based chemotherapy, highlighting the clinical relevance of targeting Clk kinases (Jiang et al., 2024).

Mechanism of Action of TG003

TG003 is a potent, ATP-competitive inhibitor of the Clk family kinases, with highest selectivity for Clk1 (IC₅₀ = 20 nM), Clk4 (15 nM), and Clk2 (200 nM), but poor activity against Clk3 (>10 μM) (APExBIO). The compound inhibits Clk-mediated phosphorylation of SR proteins, including SF2/ASF, leading to modulation of alternative splicing events such as β-globin pre-mRNA splicing. TG003 also inhibits casein kinase 1 (CK1), though with less selectivity (APExBIO).

In cells, TG003 reversibly blocks SR protein phosphorylation and alters nuclear speckle localization of Clk1, affecting the spatial regulation of splicing machinery. In vivo, TG003 modulates alternative splicing and can rescue developmental abnormalities induced by Clk overexpression, as demonstrated in Xenopus laevis embryos (APExBIO).

Evidence & Benchmarks

TG003 inhibits Clk1 with an IC₅₀ of 20 nM, Clk2 at 200 nM, Clk4 at 15 nM, and shows negligible activity for Clk3 (>10 μM) (APExBIO).
ATP-competitive inhibition confirmed with a K_i of 0.01 μM for Clk1/Sty (APExBIO).
Suppresses Clk1-mediated phosphorylation of SF2/ASF and modulates β-globin pre-mRNA splicing (APExBIO).
Alters nuclear speckle localization of Clk1 and reversibly inhibits SR protein phosphorylation in cell models (APExBIO).
In Xenopus laevis embryos, rescues developmental defects induced by Clk overexpression (APExBIO).
In mouse models, modulates alternative splicing in vivo (APExBIO).
Promotes exon 31 skipping in Duchenne muscular dystrophy models, supporting exon-skipping therapy research (APExBIO).
Elevated Clk2 in ovarian cancer correlates with platinum resistance; targeting Clk2 overcomes platinum resistance in OC cells (Jiang et al., 2024).
Clk2 phosphorylates BRCA1 at Ser1423, enhancing DNA damage repair and conferring platinum resistance in ovarian cancer (Jiang et al., 2024).
Solubility: insoluble in water, soluble in DMSO (≥12.45 mg/mL) and ethanol (≥14.67 mg/mL with ultrasonication) (APExBIO).
Recommended dosing: 10 μM for cell-based assays (DMSO as solvent); 30 mg/kg for animal studies (subcutaneous, in DMSO/Solutol/Tween-80/saline) (APExBIO).

This article extends prior coverage, such as 'TG003: A Selective Clk1 Inhibitor Transforming Splice Site Research', by integrating the latest evidence on TG003's ability to modulate platinum resistance in ovarian cancer, as well as clarifying its selectivity profile and in vivo performance. For a broader context on TG003's applicability in cancer models, see 'TG003: Selective Clk1 Inhibitor Empowering Splice Modulation', which this article updates by providing stricter benchmarks and application limits. Additionally, the comprehensive dosing and solubility data presented here refine and expand upon workflows described in 'TG003: A Selective Clk1/2 Inhibitor for Splice Site Modulation'.

Applications, Limits & Misconceptions

TG003 is primarily used for:

Dissecting Clk-mediated phosphorylation pathways in alternative splicing research.
Developing and validating exon-skipping therapies, especially for Duchenne muscular dystrophy (APExBIO).
Interrogating mechanisms of platinum resistance in ovarian cancer by targeting Clk2-regulated DNA repair (Jiang et al., 2024).
Exploring the spatial regulation of SR proteins and nuclear speckle dynamics.

Common Pitfalls or Misconceptions

Limited effect on Clk3: TG003 is not suitable for models where Clk3 inhibition is required, as IC₅₀ >10 μM suggests minimal activity (APExBIO).
Water-insoluble: Direct dissolution in aqueous buffers is ineffective; must first dissolve in DMSO or ethanol with ultrasonication (APExBIO).
Non-permanent inhibition: TG003 is a reversible inhibitor and does not permanently modify Clk enzymes or SR proteins.
Not a general splicing inhibitor: TG003 specifically targets Clk-family kinases; other splicing mechanisms may not be affected.
In vivo dosing requires careful vehicle selection: DMSO/Solutol/Tween-80/saline mixture required for animal studies; improper formulation can affect bioavailability (APExBIO).

Workflow Integration & Parameters

TG003 (B1431) is supplied as a solid by APExBIO and should be stored at -20°C. Solutions are recommended for short-term use due to stability concerns (APExBIO). For cell-based experiments, TG003 is used at 10 μM in DMSO, ensuring complete dissolution before dilution into culture medium. For animal studies, a suspension of 30 mg/kg in a vehicle (DMSO, Solutol, Tween-80, saline) is administered subcutaneously. The actual solubility may vary slightly based on laboratory conditions.

Researchers should validate solubility and dosing in their specific system. TG003's selectivity profile and robust performance in both in vitro and in vivo models make it a preferred tool for studies requiring precise modulation of Clk1/2 activity.

Conclusion & Outlook

TG003, as distributed by APExBIO, is an established, selective Clk1/2 inhibitor with well-characterized potency, selectivity, and workflow parameters. It is widely used for research on alternative splicing modulation, exon-skipping therapy, and cancer resistance mechanisms, particularly platinum resistance in ovarian cancer. Ongoing research continues to clarify the therapeutic potential of Clk inhibition in diverse disease models, making TG003 a cornerstone reagent in the field (APExBIO).